BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33845362)

  • 1. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
    Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
    ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
    Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
    Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
    Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
    Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.
    McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES
    J Clin Oncol; 2002 Apr; 20(7):1838-44. PubMed ID: 11919242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
    Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
    Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
    Maestá I; Nitecki R; Desmarais CCF; Horowitz NS; Goldstein DP; Elias KM; Berkowitz RS
    Gynecol Oncol; 2020 May; 157(2):372-378. PubMed ID: 32037196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy.
    Wu X; Qin J; Shen T; Fei W; Chen L; Xie X; Lu W
    J Gynecol Oncol; 2020 Jul; 31(4):e36. PubMed ID: 32026657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia.
    Phianpiset R; Ruengkhachorn I; Kuljarusnont S; Jareemit N; Udompunturak S
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e495-e506. PubMed ID: 35253996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
    Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
    Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
    Poli JG; Paiva G; Freitas F; Mora P; Velarde LGC; Junior JA; Filho JR; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2021 Sep; 162(3):638-644. PubMed ID: 34266689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
    Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
    Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors related to treatment outcomes in low-risk gestational neoplasia.
    Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).
    McGrath S; Short D; Harvey R; Schmid P; Savage PM; Seckl MJ
    Br J Cancer; 2010 Mar; 102(5):810-4. PubMed ID: 20160727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
    Lurain JR; Schink JC
    J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
    Deng L; Zhang J; Wu T; Lawrie TA
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD005196. PubMed ID: 23440800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
    Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
    Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid.
    Taylor F; Grew T; Everard J; Ellis L; Winter MC; Tidy J; Hancock BW; Coleman RE
    Eur J Cancer; 2013 Oct; 49(15):3184-90. PubMed ID: 23870384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
    Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
    Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.